<DOC>
	<DOC>NCT02328183</DOC>
	<brief_summary>The objective of the study is to evaluate the efficacy of Polymyxin B for treatment Gram negative bacterial infection. The hypothesis of study is Polymyxin B would be the new antibacterial agents for Thai Gram negative infected patients in case of desirable outcomes and minimal side effects.</brief_summary>
	<brief_title>Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria</brief_title>
	<detailed_description>- Investigator is notified by doctors who take care of gram negative infected patients. - Investigator inform patient or their relatives about all topics in project, eligible criteria, method, material and monitoring treatment. - After patient or their relatives are appreciated to join this project, investigator collect data in case record form;electronics form, then implement the drug. - Duration of treatment is determined by site and severity of infection, approximately 7-14 days. - Sample size calculation, by prevalence formula, we estimate the mortality rate about 50 %, deviation 10 %,and 2-sided 95% Confidence interval, therefore,97 persons - We estimate gather data about 100 persons. - Statistical descriptive analysis for descriptive data. - During the study is performing, all unexpected adverse event definitely report to Siriraj institutional Review Board immediately, in addition to subjects or their relatives.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cross Infection</mesh_term>
	<mesh_term>Polymyxin B</mesh_term>
	<mesh_term>Polymyxins</mesh_term>
	<criteria>Age 1875 yearold The infection caused by carbapenemresistant (CR) Enterobacteriaceae, CR P.aeruginosa or CR A. baumannii which susceptible to colistin The duration of treatment approximately between 714 days Kidney function, according to Kidney Disease Improving Global Outcomes (KDIGO) classification, should less than stage 4 and no replacement therapy in all modality. The patients are anticipated to live more than 48 hrs after participation. In case of Colistin administration beforehand, it should not exceed 24 hrs. All of participants should be willing to join this project. Pregnancy and lactation End stage renal disease who take renal replacement therapy Any type of Neuromuscular disease Body mass index exceed 30 Infection that require treatment more than 14 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>polymyxin B</keyword>
	<keyword>carbapenem resistant bacteria</keyword>
</DOC>